Table 5.
Distribution of clinical manifestations according to HLA-B*51 and HLA-A status
| Patient subset | n (%) of clinical manifestations | OR (95% CI) | P |
|---|---|---|---|
| Skin lesions | |||
| B*51+ A*02:07+ | 8/8 (100) | NA | 0.20 |
| B*51- A*02:07+ | 17/19 (89.5) | 2.86 (0.63 to 13.10) | 0.24 |
| B*51+ A*02:07- | 63/73 (86.3) | 2.12 (0.97 to 4.64) | 0.055 |
| B*51- A*02:07- | 92/123 (74.8) | (referent) | |
| Uveitis | |||
| B*51+ A*26:01+ | 4/7 (57.1) | 3.10 (0.66 to 14.53) | 0.21 |
| B*51- A*26:01+ | 11/19 (57.9) | 3.20 (1.19 to 8.59) | 0.017 |
| B*51+ A*26:01- | 33/74 ((44.6) | 1.87 (1.03 to 3.40) | 0.039 |
| B*51- A*26:01- | 37/123 (30.1) | (referent) |
CI, confidence intervals; NA, not applicable; OR, odds ratio.